FeesSafety
Pluang+

IGI submits IND to FDA for ISB 2301, a novel immune therapy targeting solid tumors, with Phase 1 trial planned in 2027

Company Fundamentals
17 Nov 2026, 16:10 WIB
GlobeNewsWire
View Source
Bullish
IGI submits IND to FDA for ISB 2301, a novel immune therapy targeting solid tumors, with Phase 1 trial planned in 2027

Ichnos Glenmark Innovation (IGI) has submitted an Investigational New Drug (IND) application to the U.S. FDA for ISB 2301, a first-in-class multispecific immune cell activator designed to target three tumor-associated antigens and activate both T cells and natural killer cells. This innovative therapy aims to tackle the complexity and immune resistance of solid tumors by combining multiple tumor-targeting and immune-engaging functions in one molecule. Preclinical studies showed promising safety and anti-cancer activity, supporting IGI's plan to start a Phase 1 clinical trial in patients with solid tumors in 2027. This milestone advances IGI's pipeline of novel oncology treatments using its proprietary BEAT® technology platform.

Ichnos Glenmark Innovation's IND submission for a novel immune cell activator is noted here with Pluang's Health-sector market data as of Nov 17, 2026 21:01 WIB: Out of 150 priced US health stocks, 40 rose and 103 fell. Notable movers include SYRE at USD 86.93 with a 12.52% decline and a typical hold time of 6 days, NUWE at USD 4.40 down 4.76%, and NTRA at USD 300.42 up 4.14% with 100% buy order activity and a 10-day typical hold time.

More News

Adagene and City of Hope launch Phase 1 trial for new colorectal cancer combo therapy.

Adagene and City of Hope launch Phase 1 trial for new colorectal cancer combo therapy.

Adagene Inc. and City of Hope have started a Phase 1 clinical trial testing a new combination therapy for metastatic colorectal cancer patients resistant to standard treatments. The trial evaluates two experimental drugs, ivonescimab and muzastotug (...

Others
Bullish
1 hour ago
Provident Bank appoints three leaders to boost commercial banking growth and services.

Provident Bank appoints three leaders to boost commercial banking growth and services.

Provident Bank announced three key leadership appointments to strengthen its Commercial Banking division. Edward Galan will lead Middle Market Lending, Dawn Scocco will manage portfolio and credit risk, and John Maio will head Treasury Management Ser...

Market News
Bullish
1 hour ago
RoyaLand launches its first mobile game Palazzo Chronicles: Match 3 on Google Play.

RoyaLand launches its first mobile game Palazzo Chronicles: Match 3 on Google Play.

RoyaLand Company Ltd. has released its first mobile game, Palazzo Chronicles: Match 3, on the Google Play Store. The free-to-play match-3 puzzle game features over 270 levels where players restore a royal palace set in Risorgimento Italy. This launch...

Others
Bullish
1 hour ago
Atiq Khan joins Dune as Director of Engineering to lead real-time onchain market data development.

Atiq Khan joins Dune as Director of Engineering to lead real-time onchain market data development.

Atiq Khan, with over 25 years in financial technology including roles at Goldman Sachs and Coinbase, has joined Dune as Director of Engineering. He will lead the engineering efforts behind Dune Market Data Feeds, which provide real-time trade and liq...

Others
Bullish
1 hour ago
BlackRock increases voting rights in ICG PLC to 5.16% as of November 13, 2026

BlackRock increases voting rights in ICG PLC to 5.16% as of November 13, 2026

BlackRock, Inc. has increased its total voting rights in ICG PLC to 5.16% as of November 13, 2026, up from 5.17% previously reported. This includes 5.08% voting rights attached to shares and 0.08% through financial instruments. The notification was o...

Market News
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App